|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM064400573 |
| 003 |
DE-627 |
| 005 |
20250128122248.0 |
| 007 |
tu |
| 008 |
231221s1984 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0215.xml
|
| 035 |
|
|
|a (DE-627)NLM064400573
|
| 035 |
|
|
|a (NLM)6463064
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Brooks, S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Comparison of bone levels after intramuscular administration of cephradine ('Velosef') or flucloxacillin/ampicillin in hip replacement
|
| 264 |
|
1 |
|c 1984
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 20.09.1984
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Serum and bone levels of antibiotics were measured after the intramuscular injection of either 1 g cephradine or 500 mg flucloxacillin plus 500 mg ampicillin in 48 patients undergoing total hip replacement. The results showed that both regimens produced adequate blood levels, but that the levels after cephradine were higher and more prolonged. Bone levels of cephradine were significantly higher than for flucloxacillin or ampicillin. In half of the patients studied, flucloxacillin bone levels were below the limit of detection in both cancellous and cortical bone samples. In all 24 patients, cortical levels of cephradine were satisfactory for anti-staphylococcal activity although cancellous levels were unsatisfactory in 4 patients. The penetration of the antibiotics was greater into cortical bone than into cancellous bone
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Comparative Study
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Cephalosporins
|2 NLM
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a Floxacillin
|2 NLM
|
| 650 |
|
7 |
|a 43B2M34G2V
|2 NLM
|
| 650 |
|
7 |
|a magnapen
|2 NLM
|
| 650 |
|
7 |
|a 56749-84-9
|2 NLM
|
| 650 |
|
7 |
|a Ampicillin
|2 NLM
|
| 650 |
|
7 |
|a 7C782967RD
|2 NLM
|
| 650 |
|
7 |
|a Cephradine
|2 NLM
|
| 650 |
|
7 |
|a F1BC02I72W
|2 NLM
|
| 650 |
|
7 |
|a Cloxacillin
|2 NLM
|
| 650 |
|
7 |
|a O6X5QGC2VB
|2 NLM
|
| 700 |
1 |
|
|a Dent, A R
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 3(1984), 10 vom: 20., Seite 642-9
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:3
|g year:1984
|g number:10
|g day:20
|g pages:642-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 3
|j 1984
|e 10
|b 20
|h 642-9
|